Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.

Abstract:

OBJECTIVES:Chronic obstructive pulmonary disease (COPD) is becoming a leading cause of morbidity and mortality in China. In the IMPACT trial, fluticasone furoate[FF]/umeclidinium[UMEC]/vilanterol[VI] single-inhaler triple therapy demonstrated lower rates of moderate/severe exacerbations than dual therapy with FF/VI or UMEC/VI in patients with symptomatic COPD and a history of exacerbations. This analysis investigates the China cohort and its consistency with the overall ITT population. METHODS:10,355 patients were randomized 2:2:1 to once-daily FF/UMEC/VI 100/62.5/25 µg, FF/VI 100/25 µg, or UMEC/VI 62.5/25 µg for 52 weeks. Endpoints included: annual rates of exacerbations, time-to-first on-treatment moderate/severe exacerbation and change from baseline in trough forced expiratory volume in 1 s (FEV1) at Week-52. Clinical trial registration is NCT02164513 (CTT116855). RESULTS:535 patients (5.2%) were from China. Annual on-treatment moderate/severe exacerbation rate was 0.81 with FF/UMEC/VI versus 0.96 with FF/VI (rate ratio: 0.84; 95% confidence interval [CI]: 0.64, 1.11; p = .227) and 0.80 with UMEC/VI (rate ratio: 1.02; 95% CI: 0.72, 1.44; p = .929). Hazard ratio for time-to-first moderate/severe exacerbation was 0.84 (95% CI: 0.63, 1.11; p = .218) for FF/UMEC/VI versus FF/VI and 0.89 (95% CI: 0.62, 1.27; p = .516) versus UMEC/VI. Significant improvements in mean change from baseline in trough FEV1 were observed for FF/UMEC/VI versus FF/VI (treatment difference 137 mL; 95% CI: 86, 188; p < .001) and UMEC/VI (63 mL; 0, 125; p = .050). Health status was improved with FF/UMEC/VI versus both dual therapies. Results were similar to the overall ITT population. No new safety signals were identified. CONCLUSIONS:Single-inhaler triple therapy with FF/UMEC/VI versus FF/VI or UMEC/VI reduced the rate and risk of exacerbations, and improved lung function and health status in the China cohort similar to the overall ITT population. No new safety signals were identified.

journal_name

Curr Med Res Opin

authors

Zheng J,Zhong N,Wang C,Wei LP,Zhou XD,Zhao L,Dong Yuan Y,He B,Wu B,Du X,Song J,Lipson DA

doi

10.1080/03007995.2020.1844646

subject

Has Abstract

pub_date

2021-01-01 00:00:00

pages

145-155

issue

1

eissn

0300-7995

issn

1473-4877

journal_volume

37

pub_type

杂志文章
  • New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy.

    abstract:BACKGROUND:Obesity is one of the major problems of health policy in different countries. Pharmacological attempts have been made to help affected people without a definitive solution. Some agents--either with peripheral or central effect--are available in the market. On July 2012, the FDA approved two novel preparation...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,评审

    doi:10.1185/03007995.2014.884494

    authors: Catoira NP,Viale L,Di Girolamo G,Gonzalez C

    更新日期:2014-06-01 00:00:00

  • Association between chronic pancreatitis and pyogenic liver abscess: a nationwide population study.

    abstract:BACKGROUND:The relationship between chronic pancreatitis (CP) and subsequent pyogenic liver abscess (PLA) is not well understood. METHODS:We investigated the risk of PLA in patients with CP using inpatient claims data from the Taiwan National Health Insurance Program for the period 2000-2010. We identified 17,810 pati...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1080/03007995.2016.1266312

    authors: Tseng CW,Chen YT,Lin CL,Liang JA

    更新日期:2017-03-01 00:00:00

  • Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.

    abstract:BACKGROUND:As results from an increasing number of clinical trials with disease-modifying drugs (DMDs) in multiple sclerosis (MS) become available, the challenge for the treating neurologist is how to decide on the appropriate therapy for an individual patient. OBJECTIVE:An International Working Group for Treatment Op...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,评审

    doi:10.1185/03007x233007

    authors: Goodin DS,Biermann LD,Bohlega S,Boiko A,Chofflon M,Gebeily S,Gouider R,Havrdova E,Jakab G,Karabudak R,Karussis D,Miller A,Pakdaman H,Selmaj K,Sharief M,International Working Group for Treatment Optimization in MS.

    更新日期:2007-11-01 00:00:00

  • Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.

    abstract:BACKGROUND:Triptans are not identical and migraine sufferers respond differently to different triptans. Few studies have evaluated the efficacy of switching triptans in migraine patients who have shown poor response to another agent. OBJECTIVE:To investigate the efficacy and tolerability of almotriptan 12.5 mg in pati...

    journal_title:Current medical research and opinion

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1185/030079905X65448

    authors: Diener HC

    更新日期:2005-10-01 00:00:00

  • Healthcare costs for allergic rhinitis patients on allergy immunotherapy: a retrospective observational study.

    abstract:OBJECTIVE:Subcutaneous immunotherapy (SCIT) for allergic rhinitis (AR) has been shown to control symptoms for up to several years following treatment discontinuation, but the effect of SCIT on healthcare costs for commercially insured patients is unknown. The objective of this study was to compare healthcare costs and ...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1080/03007995.2017.1359517

    authors: Allen-Ramey F,Mao J,Blauer-Peterson C,Rock M,Nathan R,Halpern R

    更新日期:2017-11-01 00:00:00

  • A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome.

    abstract::The effect of spironolactone in the alleviation of the symptoms of the premenstrual syndrome was compared with placebo in a double-blind, parallel group controlled study. One tablet daily of 100 mg spironolactone or placebo was given to 63 women from Day 12 of the menstrual cycle until the first day of the next menstr...

    journal_title:Current medical research and opinion

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1185/03007998709112403

    authors: Vellacott ID,Shroff NE,Pearce MY,Stratford ME,Akbar FA

    更新日期:1987-01-01 00:00:00

  • Appropriate use of information in therapeutic decision-making: reflections on indirect comparisons.

    abstract::Although the statistical strength of direct comparative randomized controlled trials is generally acknowledged, the particular demands of therapeutic decision making will often require indirect comparisons to be made, based on pooled data from multiple trials. As for all post-hoc analyses, the process of indirect comp...

    journal_title:Current medical research and opinion

    pub_type: 社论

    doi:10.1185/03007995.2014.1002559

    authors: Belsey JD

    更新日期:2015-02-01 00:00:00

  • A comparative study of beclomethasone dipropionate aqueous nasal spray with terfenadine tablets in seasonal allergic rhinitis.

    abstract::Forty-nine patients participated in a randomized double-blind, parallel group comparison of beclomethasone dipropionate aqueous nasal spray with terfenadine tablets in the treatment of hay fever. Symptom scores for nasal and ocular symptoms as well as grass pollen counts were registered daily for at least 1 month. Eva...

    journal_title:Current medical research and opinion

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1185/03007998509109635

    authors: Beswick KB,Kenyon GS,Cherry JR

    更新日期:1985-01-01 00:00:00

  • Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population.

    abstract:OBJECTIVE:To describe dosing patterns of etanercept, adalimumab, and infliximab in rheumatoid arthritis (RA) patients in US managed care. METHODS:This retrospective analysis included adult (18-64 years) RA patients in the HealthCore Integrated Research Database with ≥ 1 claim for etanercept, adalimumab, or infliximab ...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1185/03007995.2013.786693

    authors: Fisher MD,Watson C,Fox KM,Chen YW,Gandra SR

    更新日期:2013-05-01 00:00:00

  • Adrenocortical function after stimulation with synthetic ACTH.

    abstract::In order to assess the effect of ACTH on the adrenal cortex when used as a therapeutic or diagnostic agent, adrenocortical function was tested before and 2 hours after 0.5 mg tetracosactrin given intramuscularly in 31 healthy children, divided into 4 groups according to age and sex. Mean plasma cortisol levels were sh...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1185/03007997709115283

    authors: Tsvetkova V

    更新日期:1977-01-01 00:00:00

  • Predictive model for the Migraine-ACT questionnaire in primary care.

    abstract:BACKGROUND:Migraine is frequently under-treated. The 4-item Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire is a simple, patient-friendly tool to identify patients requiring change in acute migraine treatment. OBJECTIVE:To establish a predictive model for the Migraine-ACT questionnaire in primary c...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1185/030079907X242791

    authors: Pascual J,Láinez MJ,Baos V,García ML,López-Gil A

    更新日期:2007-12-01 00:00:00

  • Good publication practice guidelines for medical communications agencies: a MedComm perspective.

    abstract:BACKGROUND:Physicians and other health care personnel rely on the peer-reviewed biomedical literature as a key source for making clinical decisions. Thus, ensuring that the nonclinical and clinical findings published in biomedical journals are reported accurately and clearly, without undue influence from commercial int...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1185/03007990802646584

    authors: Bareket-Samish A,Denny M,Ruzicka B,Bogush M,Flynn K,Glinka K,McMahon-Wise B,Schiller S,Sjostedt P,Matheson N

    更新日期:2009-02-01 00:00:00

  • Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension.

    abstract:OBJECTIVE:Most patients with hypertension require antihypertensive combination therapy to achieve BP control. This study investigated the safety and efficacy of the direct renin inhibitor aliskiren combined with the calcium channel blocker amlodipine. METHODS:Overall, 556 patients with hypertension (msDBP > or =95-<11...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,多中心研究

    doi:10.1185/03007990902785845

    authors: Littlejohn TW 3rd,Trenkwalder P,Hollanders G,Zhao Y,Liao W

    更新日期:2009-04-01 00:00:00

  • Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis.

    abstract:OBJECTIVE:To compare the effectiveness of antiresorptive agents in reducing the risk of vertebral and non-vertebral fractures using data from published meta-analyses and the technique of adjusted indirect comparisons. RESEARCH DESIGN AND METHODS:Pairs of agents were compared by adjusted indirect comparison of 0.56 [0....

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1185/030079904125003269

    authors: Wehren LE,Hosking D,Hochberg MC

    更新日期:2004-04-01 00:00:00

  • Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions.

    abstract::The effects of gemfibrozil were assessed in 27 hyperlipidaemic patients with stable peripheral arterial occlusive disease. Gemfibrozil (600 mg twice daily) was administered for 12 weeks after 2 weeks of placebo medication, thus enabling patients to act as their own controls. Serum cholesterol levels were reduced by a ...

    journal_title:Current medical research and opinion

    pub_type: 临床试验,杂志文章

    doi:10.1185/03007999009111649

    authors: Stringer MD,Steadman CA,Kakkar VV

    更新日期:1990-01-01 00:00:00

  • Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effects.

    abstract::In a double-blind study of 102 patients with a mean age of 79 years, zopiclone was compared to flunitrazepam. The patients rated their sleep in a diary. There was no statistically significant difference between the relatively low dose of 5 mg zopiclone and 1 mg flunitrazepam for eleven out of the twelve variables meas...

    journal_title:Current medical research and opinion

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1185/03007999509110492

    authors: Dehlin O,Rubin B,Rundgren A

    更新日期:1995-01-01 00:00:00

  • GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.

    abstract:OBJECTIVES:GOAL (Gauging Osteoarthritis [OA] with Limbrel*), an open-label, post-marketing study was performed to determine the overall efficacy and gastrointestinal (GI) tolerability of flavocoxid, a novel, plant-based, anti-inflammatory medication, in a 'real world' clinical practice setting. To this end, the study e...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,多中心研究

    doi:10.1185/03007991003694522

    authors: Pillai L,Burnett BP,Levy RM,GOAL Study Cooperative Group.

    更新日期:2010-05-01 00:00:00

  • Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.

    abstract:OBJECTIVE:Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) and fingolimod are approved oral disease-modifying treatments for relapsing-remitting multiple sclerosis. In phase 3 trials, DMF (DEFINE/CONFIRM) and fingolimod (FREEDOMS/FREEDOMS II) resulted in significant reductions in clinical and...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,meta分析

    doi:10.1080/03007995.2016.1248380

    authors: Fox RJ,Chan A,Zhang A,Xiao J,Levison D,Lewin JB,Edwards MR,Marantz JL

    更新日期:2017-02-01 00:00:00

  • The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis.

    abstract:BACKGROUND:Although beta-blocker therapy has been shown to improve survival in patients with chronic heart failure, this class of drugs tends to be underutilized in diabetic patients due to concerns about adverse metabolic effects, especially on glycemic control. No randomized clinical trial has specifically evaluated ...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,meta分析

    doi:10.1185/030079906X80459

    authors: Bell DS,Lukas MA,Holdbrook FK,Fowler MB

    更新日期:2006-02-01 00:00:00

  • Plasma nitrendipine concentrations in elderly normotensive volunteers after single and multiple dosing.

    abstract::An acute and chronic dosing pharmacokinetic study of the calcium antagonist nitrendipine was carried out in 8 normotensive volunteers (mean age 80.1 +/- 3.4 years) to investigate if drug accumulation occurred in the elderly. Subjects received 10 mg nitrendipine once daily by mouth for 8 days. Plasma nitrendipine conce...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1185/03007998909115210

    authors: Crome P,Baksi A,Edwards J,Marley J

    更新日期:1989-01-01 00:00:00

  • Betamethasone-I7, 2I-dipropionate ointment: an effective topical preparation in lichen ruber planus.

    abstract::A clinical evaluation was carried out in 19 patients with lichen ruber planus to assess the effectiveness of 0.05% betamethasone-17,21-dipropionate ointment in the treatment of patients whose lesions had developed resistance to prolonged treatment with 0.1% betamethasone-17-valerate ointment. The new steroid ointment ...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1185/03007997609109305

    authors: Björnberg A,Hellgren L

    更新日期:1976-01-01 00:00:00

  • Rapid onset of action of oral labetalol in severe hypertension.

    abstract::Nine patients with persistently elevated diastolic blood pressure, exceeding 130 mmHg, received an oral dose of labetalol ranging from 200 mg to 400 mg. In all patients, this produced a significant and gradual decline in recumbent systolic and diastolic blood pressure, unaccompanied by symptoms or complications, with ...

    journal_title:Current medical research and opinion

    pub_type: 临床试验,杂志文章

    doi:10.1185/03007997709110155

    authors: Ghose RR,Sampson A

    更新日期:1977-01-01 00:00:00

  • Acebutolol (400 mg) given as a single daily dose to hypertensive patients previously stabilized on 400 mg acebutolol daily in divided doses: an open multicentre study.

    abstract::An open multicentre trial was carried out in 13 hypertensive patients, who had responded satisfactorily to and been stabilized on treatment with 400 mg acebutolol daily in divided doses, to assess the effectiveness and tolerance of the same daily dosage given as a single morning dose. On admission, patients were chang...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1185/03007997709110191

    authors: Ashton WL

    更新日期:1977-01-01 00:00:00

  • Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta.

    abstract:OBJECTIVE:To compare the efficacy and safety of epoetin theta and epoetin beta in anaemic patients with chronic kidney disease, undergoing haemodialysis and previously on stable maintenance therapy with epoetin beta. METHODS:In this multicentre, randomised, controlled, double-blind study 270 haemodialysis patients wer...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1185/03007995.2010.511084

    authors: Gertz B,Kohler E,Kes P,Essaian A,Bias P,Buchner A,Elsässer R

    更新日期:2010-10-01 00:00:00

  • Eletriptan: pharmacological differences and clinical results.

    abstract::The potential advantages of eletriptan lie firstly in its lipophilicity reflected as an increased rate of absorption and Tmax compared to sumatriptan. This is manifested in a modest advantage over sumatriptan in terms of speed of onset, 2 h headache response and 2 h pain free. However, eletriptan has not yet been show...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,评审

    doi:10.1185/0300799039117004

    authors: Giffin N

    更新日期:2001-01-01 00:00:00

  • Comparative analytical characterization of two commercial human follicle-stimulating hormones extracted from human urine.

    abstract:OBJECTIVE:Pharmaceutical preparations of human menopausal gonadotrophin (hMG), urine-derived follicle-stimulating hormone (u-FSH) and highly purified u-FSH (u-FSH-HP) have been available since the early 1960s and the mid 1980s and 1990s, respectively. Another commercial preparation of u-FSH-HP, Folyrmon P, was launched...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1185/030079905X48410

    authors: Bassett R,Ceccarelli D,Crisci C,di Tria AM,Mancinelli M,Martelli F,Mendola D,Pezzotti A

    更新日期:2005-06-01 00:00:00

  • Double-blind trials of clemastine ('Tavegil') in allergic rhinitis.

    abstract::Two double-blind randomised trials are reported comparing the effectiveness of the antihistamines, clemastine and chlorpheniramine in comparable doses, in relieving the symptoms of allergic rhinitis. In the first trial, treating 58 adults seen in a general practice, both drugs were prescribed in tablet form; l mg. cle...

    journal_title:Current medical research and opinion

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1185/03007997509113659

    authors: Todd G,Hopkins P,Maclay WP

    更新日期:1975-01-01 00:00:00

  • Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.

    abstract:BACKGROUND AND SCOPE:Whether generic drug products are truly therapeutically identical and interchangeable with their innovator counterparts is still a matter of debate. This review discusses the controversies related to the criteria for bioequivalence and therapeutic equivalence. These concerns are illustrated by usin...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,评审

    doi:10.1185/03007990903116867

    authors: Meredith PA

    更新日期:2009-09-01 00:00:00

  • Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.

    abstract:OBJECTIVES:Previous systematic reviews and meta-analyses of treatments in relapsing-remitting multiple sclerosis (RRMS) derived their findings from either placebo-controlled studies only or separately from head-to-head and comparative studies. The purpose of this study is to compare annualized relapse rates (ARR) of fi...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章,meta分析

    doi:10.1185/03007995.2012.681637

    authors: Roskell NS,Zimovetz EA,Rycroft CE,Eckert BJ,Tyas DA

    更新日期:2012-05-01 00:00:00

  • Pathfinding to an optimal strategy of revascularization in primary coronary intervention in patients with multivessel disease: a network meta-analysis of randomized trials.

    abstract:OBJECTIVES:In ST-segment elevation myocardial infarction (STEMI), current guidelines discourage treatment of the non-culprit lesions at the time of the primary intervention. Latest trials have challenged this strategy suggesting benefit of early complete revascularization. We performed a Bayesian multiple treatment net...

    journal_title:Current medical research and opinion

    pub_type: 杂志文章

    doi:10.1080/03007995.2016.1260534

    authors: Komócsi A,Kehl D,d'Ascenso F,DiNicolantonio J,Vorobcsuk A

    更新日期:2017-03-01 00:00:00